There is thus convincing pre-clinical evidence that the ACE2/Ang-(1-7)/Mas1 axis negatively regulates Ang II and that it is vasoprotective, highlighting it as a potential therapeutic target in cardiovascular disease, especially in conditions associated with activation of the RAS. Here, ACE2 is linked to cardiovascular disorder.